PROs for RARE: protocol for development of a core patient reported outcome set for individuals with genetic intellectual disability.

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Nadia Y van Silfhout, Maud M van Muilekom, Clara D van Karnebeek, Lotte Haverman, Agnies M van Eeghen
{"title":"PROs for RARE: protocol for development of a core patient reported outcome set for individuals with genetic intellectual disability.","authors":"Nadia Y van Silfhout, Maud M van Muilekom, Clara D van Karnebeek, Lotte Haverman, Agnies M van Eeghen","doi":"10.1186/s13023-024-03264-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rare genetic neurodevelopmental disorders and intellectual disability (ID), collectively called genetic ID (GID), can profoundly impact daily functioning and overall well-being of affected individuals. To improve our understanding of the impact of GID and advancing both care and research, measuring relevant patient reported outcomes (PROs) is crucial. Currently, various PROs are measured for GID. Given the shared comorbidities across disorders, we aim to develop a generic core PRO set for children and adults with GID.</p><p><strong>Methods and results: </strong>Developing the generic core PRO set entails the following steps: 1) providing an overview of potentially relevant PROs by scoping reviews and qualitative research; 2) integrating and conceptualizing these PROs (i.e., describing the content of the PROs in detail) into a pilot generic core PRO set; and 3) prioritizing relevant PROs by a European Delphi survey and consensus meetings.</p><p><strong>Conclusions: </strong>This protocol presents the steps for developing a generic core PRO set for children and adults with GID. The next step involves selecting suitable patient reported outcome measures (PROMs) to adequately measure these PROs: the generic core PROM set. This generic core PROM set needs validation in the GID population, and eventually implementation in care and research, facilitating the aggregation and analysis of PRO data and guaranteeing continuous integration of the patient perspective in both care and research.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428331/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-024-03264-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Rare genetic neurodevelopmental disorders and intellectual disability (ID), collectively called genetic ID (GID), can profoundly impact daily functioning and overall well-being of affected individuals. To improve our understanding of the impact of GID and advancing both care and research, measuring relevant patient reported outcomes (PROs) is crucial. Currently, various PROs are measured for GID. Given the shared comorbidities across disorders, we aim to develop a generic core PRO set for children and adults with GID.

Methods and results: Developing the generic core PRO set entails the following steps: 1) providing an overview of potentially relevant PROs by scoping reviews and qualitative research; 2) integrating and conceptualizing these PROs (i.e., describing the content of the PROs in detail) into a pilot generic core PRO set; and 3) prioritizing relevant PROs by a European Delphi survey and consensus meetings.

Conclusions: This protocol presents the steps for developing a generic core PRO set for children and adults with GID. The next step involves selecting suitable patient reported outcome measures (PROMs) to adequately measure these PROs: the generic core PROM set. This generic core PROM set needs validation in the GID population, and eventually implementation in care and research, facilitating the aggregation and analysis of PRO data and guaranteeing continuous integration of the patient perspective in both care and research.

RARE 的 PROs:为遗传性智障患者制定一套核心患者报告结果的协议。
导言:罕见的遗传性神经发育障碍和智力障碍(ID)统称为遗传性 ID(GID),会对患者的日常功能和整体健康产生深远影响。为了更好地了解 GID 的影响,推动护理和研究工作,测量相关的患者报告结果 (PROs) 至关重要。目前,针对 GID 有多种 PROs 测量方法。鉴于各种疾病都有共同的合并症,我们的目标是为患有 GID 的儿童和成人开发一套通用的核心 PRO:开发通用核心PRO集需要采取以下步骤:1)通过范围综述和定性研究,概述可能相关的 PROs;2)将这些 PROs 整合和概念化(即详细描述 PROs 的内容),形成一套试验性通用核心 PROs;3)通过欧洲德尔菲调查和共识会议,确定相关 PROs 的优先次序:本方案介绍了为患有 GID 的儿童和成人制定一套通用核心 PRO 的步骤。下一步是选择合适的患者报告结果测量指标(PROMs)来充分测量这些PROs:通用核心PROM集。这套通用核心PROM需要在GID人群中进行验证,并最终在护理和研究中实施,以促进PRO数据的汇总和分析,并保证在护理和研究中持续融入患者视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信